ProBioGen, Immunogenesis in cell line development agreement 24-Mar-2020 By Vassia Barba Immunogenesis is tapping into ProBioGen’s manufacturing capabilities for its immuno-oncology lead candidate, as the potential treatment enters the clinic.
3M set to sell biopharma-focused CDMO for $650m 23-Dec-2019 By Nick Taylor 3M agrees to sell drug delivery contract service unit to investment group Altaris Capital Partners.
NEWS IN BRIEF Biologics CDMO completes €5m expansion in Spain 18-Dec-2018 By Staff Reporter Biologics and cell therapy CDMO, 3P Biopharmaceuticals, has expanded its facility and capabilities in Pamplona, Spain.
